Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe
4.3.2021 10:57:00 EET | Business Wire | Press release
Galderma today announced a European re-launch of Sculptra ® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients. Sculptra ® can now be used immediately following a two-minute reconstitution and with the optional addition of lidocaine for patient comfort. Previously, healthcare professionals had to wait two hours following reconstitution to administer the product. Sculptra ® now has the fastest reconstitution protocol of any injectable poly-L-lactic acid (PLLA) available in Europe, representing a significant growth opportunity for Galderma.
“Sculptra ® has been my go-to tool for treating skin laxity resulting from aging and collagen loss in my patients’ skin, helping restore a youthful appearance,” said Dr. Christoph Martschin, Dermatologist, Akademikliniken, Department of Dermatology, Stockholm, and a featured speaker at the Sculptra ® European re-launch virtual event. “This new reconstitution protocol for Sculptra ® represents an exciting benefit as we are able to save valuable clinic time for clinicians while improving overall procedure comfort for our patients.”
Collagen provides structure and support to the skin. With facial aging, the skin’s natural collagen supply may decrease and could lead to skin laxity, wrinkles and roughness as skin quality worsens.1,2 Sculptra ® is a collagen stimulator that may help replenish lost collagen by gradually stimulating and increasing an individual’s own natural collagen production, helping restore skin quality and firmness.2-5
The updated protocol is based on new data from physiochemical studies,6 as well as results from a randomized, evaluator-blinded, parallel-group, multi-center study (NCT03780244) evaluating the safety and effectiveness of two different dilutions of Sculptra ®. This study demonstrated that treatment immediately following a two-minute reconstitution using the higher reconstitution volume (9 mL including lidocaine) was well tolerated, caused less pain on injection and was comparable to that of the reference group (Sculptra ® 5 mL) in reducing wrinkle severity of nasolabial folds (NLF) at Week 48 (n=80). Additionally, the mean change in wrinkle assessment scale (WAS) from baseline (assessed by Blinded Evaluator) was similar in both Sculptra ® study groups across 48 weeks and investigator assessed improvement using the Global Aesthetic Improvement Scale (GAIS) was > 90% in both Sculptra ® study groups.
As part of this European re-launch and in line with the company’s intensified commitment to Sculptra ®, Galderma held a dedicated interactive, virtual event with over 1,000 healthcare professionals to provide additional training and support related to this new administration protocol. The event also facilitated best practice sharing among physicians based on their clinical experiences.
“We are delighted to bring this expanded Sculptra ® offering to healthcare professionals in Europe, and yesterday’s launch event was an exciting, well-attended re-introduction to Sculptra ® and Galderma’s larger aesthetics portfolio,” said Alexandre Brennan, Global Business Unit Head, Aesthetics. “We continue to build a unique and extensive aesthetics offering at Galderma, and are proud to re-launch Sculptra ® in Europe as the foundation of our portfolio alongside a range of complementary treatments to deliver impressive and long-lasting results for healthcare professionals and their patients.”
Sculptra ® was first approved in Europe in 1999, in the United States in 2009 and in Brazil in 2004. Sculptra ® is now available in more than 40 countries globally, and additional regulatory reviews of applications for Sculptra ® in various regions are ongoing.
About Sculptra
®
Sculptra
® works to stimulate the skin’s own collagen production and is suitable for increasing the volume of depressed areas, particularly to correct skin depressions such as skin creases, wrinkles, folds, scars and for skin aging. Sculptra
® is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).
Sculptra ® is an injectable biostimulator containing microparticles of Poly-L-Lactic Acid (PLLA) which gradually revitalizes the skin’s structural foundation, providing natural-looking, long-term results for up to 25 months. Sculptra ® was first approved in 1999 in Europe and it is currently available in more than 40 countries globally. To learn more about Sculptra ® products, visit www.galdermaaesthetics.com
About Galderma
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in approximately 100 countries with an extensive product portfolio of prescription medicines, aesthetic solutions and consumer care products. The company partners with healthcare professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com
- Shuster S, Black MM, McVitie E. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93:639-643.
- Bohnert K et al. Plast Reconstr Surg 2019;127(4):1684–92.
- Stein P et al. J Dermatol Sci 2015;78(1):26–33.9.
- Goldberg D et al. Dermatol Surg 2013;39(6):915–22.
- Vleggaar D et al. J Drugs Dermatol 2014;13 (4 suppl):s29–31.
- Baumann K et al. J Drugs Dermatol. 2020;19(12):1199-1203.
###
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303006096/en/
Contact information
Investor and media relations
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Media Contact
Lauren Starr
Head of Franchise Communications
media@galderma.com
+41 79 771 52 45
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release
Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl
IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 23:06:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in US dollars and 3 percent in constant currency compared to Q4 of the prior yea
Sentinel Midstream Advances Texas GulfLink Deepwater Port5.5.2026 23:00:00 EEST | Press release
Sentinel Midstream LLC (Sentinel) today announced the commencement of its Texas GulfLink deepwater port (Texas GulfLink or the Project), marking a significant milestone enabled by funding received pursuant to the U.S.—Japan Trade Agreement. The project advances in coordination with the U.S. Department of Commerce and the Government of Japan and reflects the shared commitment to strengthening global energy security and expanding U.S. export infrastructure. Sentinel will lead the development of Texas GulfLink, overseeing construction, commercial operations, and long-term management of the terminal. Funding provided under the U.S.—Japan Trade Agreement, pursuant to Executive Order 14345 signed on September 4, 2025, underscores continued international confidence in U.S. energy infrastructure and supports the expansion of American crude oil exports to global markets. Upon this commencement, Texas GulfLink will immediately begin construction of its deepwater crude oil export terminal, unlock
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom